Oregon Therapeutics

Executive Summary

Oregon Therapeutics is a Paris-based biotechnology company pioneering a first-in-class targeted cancer therapy through inhibition of Protein Disulfide Isomerase (PDI). Founded in 2018, the company has advanced its lead candidate, XCE853, to the preclinical stage, targeting cancers with specific metabolic vulnerabilities. PDI inhibition represents a novel approach to disrupt protein folding and induce ER stress in tumor cells, potentially offering a differentiated mechanism versus standard-of-care agents. Although still in early development, the company's focus on metabolic liabilities and a well-validated target positions it for potential partnership or further financing as it approaches clinical readiness. The biotechnology sector has shown increasing interest in ER stress modulation, and Oregon Therapeutics' progress in moving XCE853 toward the clinic will be a key value inflection point.

Upcoming Catalysts (preview)

• Q4 2026IND filing and initiation of Phase 1 trial for XCE85340% success
• Q2 2026Presentation of preclinical efficacy and safety data at major oncology conference70% success
• Q3 2026Series A or Series B financing round to support clinical development50% success